menu
    • menu
    [{"orgOrder":0,"company":"Armatus Bio","sponsor":"SOLVE FSHD","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Financing","leadProduct":"ARM-201","moa":"DUX4 expression","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Armatus Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Armatus Bio \/ SOLVE FSHD","highestDevelopmentStatusID":"4","companyTruncated":"Armatus Bio \/ SOLVE FSHD"},{"orgOrder":0,"company":"Armatus Bio","sponsor":"Solid Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Licensing Agreement","leadProduct":"SGT-003","moa":"Microdystrophin DNA sequence","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armatus Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Armatus Bio \/ Armatus Bio","highestDevelopmentStatusID":"7","companyTruncated":"Armatus Bio \/ Armatus Bio"},{"orgOrder":0,"company":"Armatus Bio","sponsor":"Andelyn Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Armatus Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Armatus Bio \/ Armatus Bio","highestDevelopmentStatusID":"4","companyTruncated":"Armatus Bio \/ Armatus Bio"}]

    Find Clinical Drug Pipeline Developments & Deals by Armatus Bio

    Menu

    Armatus Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Armatus Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Armatus Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARM-201

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : SOLVE FSHD

                            Deal Size : $3.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            SOLVE FSHD Invests $3M in Armatus Bio for FSHD Gene Therapy Advancement

                            Details : The financing aims to advance the ARM-201, engineered microRNA reduces toxic DUX4 expression. It is being evaluated for the treatment of FSHD.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            May 06, 2025

                            Lead Product(s) : ARM-201

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : SOLVE FSHD

                            Deal Size : $3.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Armatus Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Armatus Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SGT-003

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Recipient : Solid Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Solid Biosciences Announces Agreement with Armatus Bio for AAV-SLB101 Development

                            Details : Armatus Bio for the use of Solid’s proprietary capsid AAV-SLB101 for the development and commercialization of Armatus’ vectorized RNAi candidate to treat Facioscapulohumeral muscular dystrophy.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            March 07, 2024

                            Lead Product(s) : SGT-003

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Solid Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Armatus Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Armatus Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Recipient : Andelyn Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Andelyn and Armatus Partner to Manufacture AAV Gene Therapy for CMT1A

                            Details : Armatus will leverage Andelyn's extensive experience in adeno-associated virus (AAV) production and its proprietary suspension platform for its gene therapy for Charcot-Marie-Tooth Type 1A (CMT1A).

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 15, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : Andelyn Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth